BRANT Tests Whether Early Tirofiban Can Alter the Course of Branch Atheromatous Disease Stroke

Branch atheromatous disease-related stroke is a difficult acute stroke subtype because neurologic function can worsen after the initial event, sometimes over hours rather than days. Early neurological deterioration can convert a modest presenting deficit into a disabling infarct, leaving clinicians with little room to intervene once the process accelerates. The BRANT trial is built around that clinical problem: whether intravenous tirofiban, started within 48 hours of onset, can improve the chances of an excellent functional recovery at 90 days compared with standard antiplatelet treatment.

The rationale is straightforward and clinically urgent. In branch atheromatous disease, the occlusive process involves penetrating arterial branches and the infarct can extend along the vessel territory, creating a pattern of progression that differs from a classic embolic stroke. Platelet activation and microvascular propagation likely contribute to that evolution, which is why a rapidly acting antiplatelet strategy may be biologically plausible in the earliest phase. Tirofiban, a glycoprotein IIb/IIIa inhibitor, offers immediate platelet inhibition rather than the slower onset seen with oral agents. In a syndrome defined by early worsening, speed matters at the bedside.

A Phase III Trial Built Around Early Neurologic Deterioration

BRANT is a multicentre, randomised, open-label, blinded endpoint, parallel-controlled phase III trial conducted across 21 hospitals in China. Adults aged 18 to 75 years with acute BAD-related stroke within 48 hours of symptom onset are assigned in a 1:1 ratio to receive tirofiban or control therapy. Both groups are treated for 48 hours. The comparison is not designed to be abstract or mechanistic alone; it is aimed squarely at the clinical question physicians face when BAD-related stroke is still evolving and the window for preventing infarct extension is still open.

The trial uses an endpoint that reflects what matters most after stroke care: modified Rankin Scale score of 0 to 1 at 90 days, defined as an excellent functional outcome. That choice is important because branch atheromatous disease can produce deficits that are small at first but accumulate into meaningful disability if the lesion progresses. A treatment that reduces deterioration early could, in theory, translate into a larger share of patients returning to near-baseline independence three months later. The study’s focus on functional recovery rather than imaging alone keeps the question anchored in patient-centered outcome.

The planned sample size is 516 participants. Investigators assumed rates of the primary outcome of 74% in the tirofiban group and 62% in the control group, with 0.8 power and a two-sided alpha of 0.05. Those assumptions define the target without overstating certainty; this is still a protocol, not a result set. What matters clinically is that the trial is powered to detect a difference in recovery that would be meaningful in a condition where the acute phase often sets the long-term trajectory.

Why a Fast-Acting Antiplatelet Strategy Is Being Tested

Tirofiban’s appeal in this setting comes from its pharmacology. It blocks final common-pathway platelet aggregation and can suppress thrombus growth rapidly after infusion begins. In a stroke subtype where lesion extension may continue after arrival to hospital, that mechanism could interrupt the biological chain that drives worsening. The hypothesis is not that tirofiban reverses established infarction, but that it may prevent additional injury during the narrow interval when the tissue is still vulnerable.

The study also reflects a practical challenge in acute stroke medicine: standard antiplatelet therapy is often used because it is familiar and widely available, but familiarity does not guarantee optimal protection in every stroke mechanism. Branch atheromatous disease behaves differently from large-artery embolism and differs again from small-vessel lacunar infarction. A therapy capable of blocking platelet aggregation quickly could be particularly relevant if the pathologic process involves ongoing branch occlusion or local thrombotic propagation at the perforator origin.

Safety Signals Remain Central to the Design

The protocol does not frame tirofiban as a simple efficacy experiment. It also builds in assessment of major bleeding, stroke recurrence, death, serious adverse events, and changes in bleeding-related markers. That safety structure is essential, because any intensified antiplatelet strategy in the acute stroke period carries the obvious concern of hemorrhagic complications. A treatment that reduces neurologic deterioration but increases bleeding would not solve the clinical problem. The balance between ischemic protection and hemorrhagic risk sits at the center of the trial question.

The open-label design with blinded endpoint assessment is a sensible compromise in a multicentre randomized trial of this type. Clinicians and patients know which treatment is assigned, but the endpoint evaluation is protected from direct treatment bias. That structure helps preserve the credibility of the 90-day functional outcome while still allowing the practical realities of acute stroke care across 21 hospitals.

Enrollment Criteria Define the Population Under Study

Eligibility is limited to patients 18 to 75 years old with acute BAD-related stroke within 48 hours of onset. The age range narrows the population to adults in whom the intervention is being tested under a clearly defined acute window. The 48-hour treatment period is also notable because it concentrates exposure in the phase when deterioration often emerges, rather than extending therapy indefinitely. In practice, that means the trial is examining whether a short, early burst of potent platelet inhibition can change the downstream functional course.

Because BAD-related stroke is increasingly recognized as a distinct clinical entity, the trial addresses a gap that has practical consequences in emergency neurology and stroke units. Patients with this stroke subtype may not fit neatly into broader acute ischemic stroke treatment models, especially when early worsening is the dominant threat. BRANT is designed to determine whether the biological logic of rapid platelet blockade translates into better function, fewer deterioration events, and acceptable safety in this narrower but clinically important population.

Ethics, Registration, and the Limits of the Current Evidence

The study has ethics approval from the Ethics Committee of Peking Union Medical College Hospital, and written informed consent is required before enrolment. It is registered at ClinicalTrials.gov under NCT06037889. Results will be published in a peer-reviewed journal, but no outcomes are available yet from this protocol.

For now, the value of BRANT lies in its focus on a mechanistically coherent but unproven strategy. The trial is attempting to answer whether early intravenous tirofiban can prevent the cascade of branch atheromatous progression that leaves many patients with worse disability than the first scan or first exam suggests. Until the data mature, the central uncertainties remain the size of any functional benefit, the frequency of early neurological deterioration across treatment arms, and whether the bleeding profile stays acceptable during the acute phase of stroke care.


Reporting by Dr. A. Manasa, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.